Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 10/20 | 0.79 |
| ▸ | CYSLTR2 | Q9NS75 | 9/20 | 0.78 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.78 |
| ▸ | RECQL | P46063 | 1/20 | 0.78 |
| ▸ | BLM | P54132 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | EGFR | P00533 | 1/20 | 0.78 |
| ▸ | ESR1 | P03372 | 1/20 | 0.78 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.78 |
| ▸ | FYN | P06241 | 1/20 | 0.78 |
| ▸ | PGR | P06401 | 1/20 | 0.78 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.78 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.78 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.78 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401162 | 1.00 | CYSLTR1 (0.79) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL10054292 | 1.00 | CYSLTR1 (0.79) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL12724464 | 1.00 | CYSLTR1 (0.79) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL5002515 | 0.93 | CYSLTR1 (0.68) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL13042615 | 0.93 | CYSLTR1 (0.68) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL5002518 | 0.93 | CYSLTR1 (0.68) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL5002513 | 0.93 | CYSLTR1 (0.68) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL8761836 | 0.92 | CYSLTR1 (0.82) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL538484 | 0.92 | CYSLTR1 (0.82) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL30719989 | 0.92 | CYSLTR1 (0.82) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185517-B1 | PROCESS FOR PREPARING A LEUKOTRIENE ANTAGONIST AND AN INTERMEDIATE THEREOF | MOEHS IBERICA SL (ES) | 2012-09-19 | — | — | EP | disclosed |
| US-8163924-B2 | Process for preparing a leukotriene antagonist and an intermediate thereof | Moehs Ibérica, S.L. (ES) | 2012-04-24 | — | — | US | disclosed |
| US-8163924-B2 | Process for preparing a leukotriene antagonist and an intermediate thereof | Moehs Ibérica, S.L. (ES) | 2012-04-24 | — | — | US | disclosed |
| US-8115004-B2 | Process for pure montelukast sodium through pure intermediates as well as amine salts | MSN LABORATORIES LIMITED (IN) | 2012-02-14 | — | — | US | disclosed |
| US-7829716-B2 | decyclization of {3-[(E)-2(7-chloro-2-quinolinyl)vinyl]phenyl}-4,5-dihydro-3H-benzo[c]thiepin-1-one by methylmagnesium halide with following conversion to montelukast | Synthon Pharmaceuticals, Inc. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829716-B2 | decyclization of {3-[(E)-2(7-chloro-2-quinolinyl)vinyl]phenyl}-4,5-dihydro-3H-benzo[c]thiepin-1-one by methylmagnesium halide with following conversion to montelukast | Synthon Pharmaceuticals, Inc. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829716-B2 | decyclization of {3-[(E)-2(7-chloro-2-quinolinyl)vinyl]phenyl}-4,5-dihydro-3H-benzo[c]thiepin-1-one by methylmagnesium halide with following conversion to montelukast | Synthon Pharmaceuticals, Inc. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7786138-B2 | Process for making montelukast and intermediates therefor | SYNTHON BV (NL) | 2010-08-31 | — | — | US | disclosed |
| US-7786138-B2 | Process for making montelukast and intermediates therefor | SYNTHON BV (NL) | 2010-08-31 | — | — | US | disclosed |
| US-20100204476-A1 | Process for preparing a leukotriene antagonist and an intermediate thereof | MOEHS IBERICA S.L. (ES) | 2010-08-12 | — | — | US | disclosed |
| US-20070213365-A1 | Novel polymorphs of montelukast ammonium salts and processes for preparation therefor | CHEMAGIS LTD. (IL) | 2007-09-13 | — | — | US | disclosed |
| US-20070213365-A1 | Novel polymorphs of montelukast ammonium salts and processes for preparation therefor | CHEMAGIS LTD. (IL) | 2007-09-13 | — | — | US | disclosed |
| US-20070135480-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2007-06-14 | — | — | US | disclosed |
| US-20070135642-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2007-06-14 | — | — | US | disclosed |
| US-20070135480-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2007-06-14 | — | — | US | disclosed |
| US-20070135642-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2007-06-14 | — | — | US | disclosed |
| US-20070135643-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2007-06-14 | — | — | US | disclosed |
| US-20070135643-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2007-06-14 | — | — | US | disclosed |
| WO-2007057228-A1 | A NEW INTERMEDIATE FOR MAKING MONTELUKAST AND RELATED COMPOUNDS | SYNTHON B.V. (NL) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007004237-A2 | A PROCESS FOR THE PREPARATION OF MONTELUKAST | MATRIX LABORATORIES LTD (IN) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135480-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | LTC4S, LTA4H, CYSLTR1 | CYSLTR1 3/4885CYSLTR2 10/4885CYP2C8 773/4885 |
| US-20070135642-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | CYP4A11, CYP51A1, CYP4F11 | CYSLTR1 9/4885CYSLTR2 19/4885CYP2C8 382/4885 |
| US-20070135643-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | CMA1, CYP51A1, NOTUM | CYSLTR1 5/4885CYSLTR2 11/4885CYP2C8 792/4885 |
| US-20070213365-A1 | Novel polymorphs of montelukast ammonium salts and processes for preparation therefor | ATP6V1A, ATP6V1H, ATP6V1G1 | CYSLTR1 27/4885CYSLTR2 103/4885CYP2C8 614/4885 |
| US-20100204476-A1 | Process for preparing a leukotriene antagonist and an intermediate thereof | CYSLTR2, LTB4R2, LTA4H | CYSLTR1 6/4885CYSLTR2 1/4885CYP2C8 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.